One manuscript supporting its predictive ability in targeting the vascular endothelial growth factor (VEGF) pathway was recently published.34 In 48 patients with GC who received second-line ramicurimab/paclitaxel combination therapy the median OS was 9.5 months for carriers of TP53Inactive mutations, 8.6 months for carriers of other TP53 mutations, 6.0 months for carriers of TP53Active missense mutations, and 4.5 months for TP53WT patients (P = .01). The gene discussed is TP53; the disease is gastric cancer.